表紙
市場調査レポート

特発性(本態性)高血圧症 : パイプライン分析

Idiopathic (Essential) Hypertension - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251558
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
特発性(本態性)高血圧症 : パイプライン分析 Idiopathic (Essential) Hypertension - Pipeline Review, H1 2016
出版日: 2016年03月22日 ページ情報: 英文 68 Pages
概要

本態性高血圧症は、原発性高血圧症あるいは特発性高血圧症とも呼ばれ、 特定できる原因が無いと定義される高血圧症の一形態です。本態性高血圧症は加齢に伴って増加しますが、若い人でも比較的血圧が高ければ高血圧症を発症するリスクが高くなります。高血圧症は、大脳、心臓、腎臓に関する事故のリスクを高めます。発症の原因としては、遺伝的素因、年齢、運動不足や高脂肪食、塩分の摂り過ぎなどといった生活習慣によるものが挙げられます。肥満や運動不足の増加により、高血圧症は今後増加するものと見られています。

当レポートでは、特発性(本態性)高血圧症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

特発性(本態性)高血圧症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Bayer AG
  • Chong Kun Dang Pharmaceutical Corp.
  • Eli Lilly and Company
  • HanAll Biopharma Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lee's Pharmaceutical Holdings Limited
  • PhaseBio Pharmaceuticals, Inc.
  • Quantum Genomics SA
  • Sun Pharma Advanced Research Company Ltd.
  • Takeda Pharmaceutical Company Limited
  • TSH Biopharm Corporation Limited

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide)
  • (amlodipine besylate + candesartan cilexetil)
  • (amlodipine besylate + hydrochlorothiazide + losartan potassium)
  • (atorvastatin calcium + losartan potassium)
  • (nifedipine + candesartan cilexetil)
  • azilsartan medoxomil
  • carvedilol phosphate ER
  • carvedilol phosphate SR
  • CRTA-04
  • LY-2623091
  • PB-1046
  • PB-1120
  • QGC-001
  • rostafuroxin

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7744IDB

Summary

Global Markets Direct's, 'Idiopathic (Essential) Hypertension - Pipeline Review, H1 2016', provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
  • The report reviews pipeline therapeutics for Idiopathic (Essential) Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Idiopathic (Essential) Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Idiopathic (Essential) Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Idiopathic (Essential) Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Idiopathic (Essential) Hypertension Overview
  • Therapeutics Development
    • Pipeline Products for Idiopathic (Essential) Hypertension - Overview
  • Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies
  • Idiopathic (Essential) Hypertension - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Idiopathic (Essential) Hypertension - Products under Development by Companies
  • Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Bayer AG
    • Chong Kun Dang Pharmaceutical Corp.
    • Daiichi Sankyo Company, Limited
    • Eli Lilly and Company
    • HanAll Biopharma Co., Ltd.
    • Innopharmax Inc.
    • Lee's Pharmaceutical Holdings Limited
    • PhaseBio Pharmaceuticals, Inc.
    • Quantum Genomics SA
    • Sun Pharma Advanced Research Company Ltd.
    • Takeda Pharmaceutical Company Limited
  • Idiopathic (Essential) Hypertension - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (amlodipine besylate + candesartan cilexetil) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (amlodipine besylate + hydrochlorothiazide + losartan potassium) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (atorvastatin calcium + losartan potassium) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (candesartan cilexetil + nifedipine) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • azilsartan medoxomil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carvedilol phosphate CR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carvedilol phosphate SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CS-3150 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lisinopril - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LY-2623091 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-1046 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-1120 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QGC-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rostafuroxin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Idiopathic (Essential) Hypertension - Recent Pipeline Updates
  • Idiopathic (Essential) Hypertension - Dormant Projects
  • Idiopathic (Essential) Hypertension - Product Development Milestones
    • Featured News & Press Releases
      • Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure
      • Jun 12, 2013: Lee's Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Innopharmax Inc., H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Quantum Genomics SA, H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Idiopathic (Essential) Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Idiopathic (Essential) Hypertension Therapeutics - Recent Pipeline Updates, H1 2016
  • Idiopathic (Essential) Hypertension - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top